October 28, 2016 4:34pm
… Doesn’t help the lingering fear of getting through and advancing beyond P2s
While the market dipped as the FBI renews review of Clinton emails
I answer one question; in which company should investors put, keep and commit their money!
Lose a pricing or investment advantage or be a subscriber! Today’s results have implications to Monday's sector activity.
There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.
I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
U.S. equities closed mostly lower on Friday after the Federal Bureau of Investigation announced it is investigating new emails related to Democratic nominee Hillary Clinton.
The NASDAQ closed DOWN -25.87 or -0.50% to 5,190.10 and the DOW closed DOWN -7.74 or -0.04% to 18,161.94.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
· The open was negative with an A/DL of 11/25 and 7 flats;
· The mid-day stayed negative with an A/DL of 19/22 and 2 flats;
· The closing bell was negative with A/DL of 16/22 and 5 flats;
Henry’omics:
The FBI reopened the e-mail case of Hillary Clinton which knocked 154 points from the market <around 1:10 p.m.> to its knees beyond the mid-day which also upsets any balance in next 11 days to the election? That's what the market is worried about. The market did recover from its spasm at about 3:05 p.m.!
- The stem, cell, gene and regenerative therapy (SCGT&RT) sector opened negative, stayed negative at the mid-day and closed negative.
Slipping and sliding, another down session to since last Friday – six (6) and counting!
- Another issue is … sector stocks have remained in a tight range over the past month, while the market moved higher, lower and sideways.
When you see days, weeks and a month like this ... tells you that traders control the story of share pricing.
- As I stated this a.m. – “The SCG&RT sector is rotating even further down after five down days, with an analogy to – no news is good news and bad news is sold into. For the remainder of this month, quarter and year since I have outlined the weaknesses of the “current” share pricing positions - this breakdown has been grounded in speculation to the downside and won’t be broken easily.”
Reiterating, I perceive that we will be seeing more of … a tug of war between Q3 reporting of cash positions and share pricing – it will be all about … “runways”.
- Regardless of the news we got today re Opexa (OPXA); next week, Q3 quarterly reporting … WILL be the story for the next 30 days.
The iShares Russell 2000 (IWM) indicated a negative pre- open -0.47% and was DOWN -0.28% at the close while the iShares Nasdaq Biotechnology (IBB) indicated a negative pre-open -0.55% and closed down -1.66%.
Look close at today and the past days – trading ranges - I see patterns:
The downside trend reflects a pricing trend range of:
· Friday’s declines from -0.43% to -7.88% <excepting a -69.12 related to OPXA> in 22 equities;
· Thursday’s declines ranged from -0.16% to -16.50% in 30 equities;
· Wednesday’s decliners ranged from -0.24% to -5.36% in 28 equities;
· Tuesday’s decliners ranged from -0.20% to -12.82% in 28 equities;
· Monday’s decliners ranged from -0.04% to -5.33% in 27 equities;
· Last Friday’s decliners ranged from -0.24% to -13.11% in 23 equities;
The upside shows a pricing trend range of:
· Friday’s advances ranged from +0.40% to +5.26% in 16 equities;
· Thursday’s advancers ranged from +0.24% to 4.48% in 10 equities;
· Wednesday’s advancers ranged from +0.14% to +9.09% in 14 equities;
· Tuesday’s advancers ranged from +0.31% to +7.89% in 9 equities
· Monday’s advancers ranged from +0.26% to +27.04% in 10 equities;
· Last Friday’s advancers ranged +0.24% to +4.26% in 17 equities;
Wrap-up: Friday’s scoreboard <43 companies reporting> Friday’s 16 gains relate to Thursday’s 10 gains as compared to Wednesday’s 14 versus Tuesday’s 9 gains matched by Monday’s 10 with so-so volume; while Friday’s 22 gains relates to Thursday’s 30 number defining further weakness backed by Wednesday’s downside of 28 compared to Tuesday’s 28 compared to Monday’s 27 with moderate volume.
Friday, Thursday, Wednesday, Tuesday, Monday and Friday were DOWN days, walking past a strong upside on the previous Thursday …
Percentage decliners:
· Opexa (OPXA) -69.12% after Thursday’s +4.48% after Wednesday’s -2.76%;
· StemCells (STEM) -7.88%;
· Sangamo Biosciences (SGMO) -6.67%;
· ImmunoCellular (NYSEMKT: IMUC) -6.38%;
· Organovo (ONVO) -4.76%;
Percentage advancers:
· Fibrocell (FCSC) +5.56%;
· ReNeuron (RENE.L) +5.26%;
· Verastem (VSTM) +4.10%;
· VistaGen (VTGN) +3.90%;
· Capricor (CAPR) +3.83%
Flat:
· BioLife Solutions (BLFS) at $1.66;
· BioTime (NYSEMKT: BTX) at $3.33;
· Pluristem (PSTI) at $1.60;
· Stemline (STML) at $11.78;
· Vericel (VCEL) at $2.30;
Review my fear gauge or the CBOE Volatility Index (VIX):
· Friday traded near 16.9;
· Thursday traded near 14.9;
· Wednesday traded near 14.6;
· Tuesday traded near 13.6. The index was on track to snap a five-day losing streak;
· Monday traded near 13;
· Last Friday traded near 13.5;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
